Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF – Get Free Report) shares traded up 27.3% on Wednesday . The stock traded as high as $15.63 and last traded at $15.63. 2,000 shares were traded during trading, an increase of 529% from the average session volume of 318 shares. The stock had previously closed at $12.2750.
Santhera Pharmaceuticals Price Performance
The firm’s 50-day simple moving average is $13.40 and its 200 day simple moving average is $14.94.
About Santhera Pharmaceuticals
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative therapies for rare neuromuscular and pulmonary diseases. Headquartered in Pratteln, Switzerland, the company concentrates on addressing high unmet medical needs in conditions such as Duchenne muscular dystrophy (DMD), limb‐girdle muscular dystrophies and other mitochondrial or neuromuscular disorders. Santhera’s corporate strategy emphasizes both in‐house development and strategic partnerships to advance its drug candidates through clinical trials and bring approved therapies to market.
The company’s flagship marketed product is Raxone (idebenone), a synthetic analogue of coenzyme Q10 that received marketing authorization in Europe for the treatment of visual impairment in patients with Leber’s hereditary optic neuropathy (LHON).
Featured Stories
- Five stocks we like better than Santhera Pharmaceuticals
- A month before the crash
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Wall Street Alert: Buy AES
- Bitcoin is down but your income is about to explode
- Trump Devises the Death of the IRS ☠️
Receive News & Ratings for Santhera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santhera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
